<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127913">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02114775</url>
  </required_header>
  <id_info>
    <org_study_id>13-0324</org_study_id>
    <nct_id>NCT02114775</nct_id>
  </id_info>
  <brief_title>Growth Hormone or Sildenafil as Therapies for Fatigue in Mild-â€‹Traumatic-brain-injury (MTBI)</brief_title>
  <official_title>Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal is to determine whether perceptual or performance fatigue can be reduced in
      MTBI patients with and without growth hormone (GH) deficiency by treating them in a
      crossover fashion based upon GH status.

      A battery of functional, fatigue, cognitive and blood flow tests will be performed to assess
      the efficacy of the two drug interventions, Growth hormone and Sildenafil.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Perceptual fatigue as measured weekly using the Brief Fatigue Inventory</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using hand and leg dynamometry.</measure>
    <time_frame>up to  12  months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <other_name>Genotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female with a diagnosis of mild TBI and 6 month post-injury. Age 18 to 60 years.
        Complaint of fatigue, with score of 3 or greater on questions 1, 2, or 3 of the Brief
        Fatigue Inventory.

        Exclusion Criteria:

        Exclusion criteria (general)

          1. Significant heart, liver, kidney, blood or respiratory disease.

          2. Active coronary disease.

          3. Pregnancy.

          4. Alcohol or drug abuse.

          5. Unable to walk unassisted.

          6. Diabetes mellitus and anterior pituitary abnormalities diagnosed upon screening.

          7. Premorbid history of psychiatric disorder.

          8. Premorbid history of head trauma.

        Exclusion criteria (sildenafil/placebo group)

          1. Use of nitrates.

          2. Use of alpha blockers.

          3. Systolic blood pressure &lt;100 or &gt;150, diastolic blood pressure &lt;60 or &gt;90.  This
             range is smaller than the acceptable range stated in the prescribing information for
             sildenafil (&gt;90/50 and &lt;170/110).

          4. Peripheral vascular disease.

          5. Use of a phosphodiesterase 5 inhibitor.

        Exclusion criteria (growth hormone/placebo group)

          1. Coumadin because of the risk of bleeding with daily injections of   Recombinant Human
             Growth Hormone (rhGH) in the growth hormone (GH) arm of the study.

          2. Subjects who are deficient in cortisol or thyroid at screening will be excluded until
             hormone abnormalities have been corrected.

          3. Subjects with chronic pain who are being managed with narcotics will be excluded as
             the effects of central nervous system depressants may interfere with study test
             results.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melinda Sheffield-Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brent Masel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transitional Learning Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Gilkison, NP</last_name>
    <phone>409-772-2065</phone>
    <email>cgilkiso@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Randolph, BS</last_name>
    <phone>409-772-8126</phone>
    <email>kmrandol@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Gilkison, NP</last_name>
      <phone>409-772-2065</phone>
      <email>cgilkiso@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kate Randolph, BS</last_name>
      <phone>409-772-8126</phone>
      <email>kmrandol@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randall Urban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melinda Sheffield-Moore, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild traumatic brain injury</keyword>
  <keyword>growth hormone</keyword>
  <keyword>fatigue</keyword>
  <keyword>sildenafil</keyword>
  <keyword>neurology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
